行情

PLX

PLX

PROTALIX生物疗法
AMEX
1.130
+0.030
+2.73%
休市 16:00 12/02 EST
开盘
1.090
昨收
1.100
最高
1.150
最低
1.090
成交量
5.92万
成交额
5.51万
52周最高
2.000
52周最低
0.7000
市值
5,725.21万
市盈率(TTM)
-2.9589
分时
5日
1月
3月
1年
5年
美股异动 | Protalix生物治疗(PLX.US)涨62.86% 治疗法布里病PRX-102疗法临床试验获得积极数据
美股异动 | Protalix生物治疗(PLX.US)涨62.86% 治疗法布里病PRX-102疗法临床试验获得积极数据
格隆汇 · 04/04 13:50
Protalix BioTreateutics(PLX.US)治疗法布里病PRX-102疗法获得临床积极数据
Protalix BioTreateutics(PLX.US)治疗法布里病PRX-102疗法获得临床积极数据
格隆汇 · 04/04 12:25
PLX 简况
Protalix Biotherapeutics Inc is an Israel-based biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system. Its system represents a new method for developing recombinant proteins in an industrial-scale manner. Company's aim is to develop tailored complex recombinant therapeutic proteins primarily produced through ProCellEx (platform). Through its platform Protalix Biotherapeutics Inc develops Elelyso, for the treatment of Gaucher disease as well as a pipeline of products such as, pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease is in advanced clinical stages.

微牛提供Protalix Biotherapeutics Inc(AMEX-PLX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PLX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PLX股票基本功能。